A Novel Gene-Therapy Approach to ‘Functionally Cure’ HIV Succeeds in some Monkeys

Why It Matters

A functional cure could dramatically lower the global burden of HIV treatment and reshape investment in gene‑therapy platforms for infectious diseases.

Key Takeaways

• Six of 19 monkeys achieved viral suppression.
• Single low-dose AAV injection showed no serious toxicity.
• Antidrug antibodies limited efficacy in twelve monkeys.
• CCR5 blockade mimics natural resistance mutation.
• Combination with broadly neutralizing antibodies may enhance cure.

Pulse Analysis

The CCR5 co‑receptor is a well‑validated gateway for HIV entry, and individuals homozygous for the CCR5Δ32 mutation are virtually immune to infection. Leveraging this natural protection, scientists have engineered an adeno‑associated virus (AAV) vector to deliver a gene encoding a potent CCR5‑blocking antibody directly into muscle cells. AAV platforms have already secured approvals for rare genetic disorders, offering a durable, potentially lifelong expression of therapeutic proteins without integrating into the host genome.

In the latest pre‑clinical trial, a single low‑dose intramuscular AAV injection led to sustained antibody production in six out of nineteen macaques, suppressing SHIV replication for more than twelve months. Importantly, the treated animals exhibited no serious adverse events, contrasting with higher‑dose AAV regimens that have caused liver toxicity in other settings. However, twelve monkeys mounted robust antidrug antibody (ADA) responses that neutralized the therapeutic protein, underscoring the immunogenicity challenge. Intriguingly, four ADA‑positive subjects later re‑expressed the antibody months after the initial decline, hinting at possible immune tolerance mechanisms that merit deeper investigation.

If translated to humans, this strategy could reduce or eliminate the need for daily antiretroviral therapy, lowering costs and improving quality of life for millions. Experts argue that pairing the CCR5 antibody gene with broadly neutralizing antibody (bNAb) constructs may overcome residual viral reservoirs and ADA hurdles. The field now faces regulatory scrutiny over vector safety, long‑term monitoring, and the development of controllable “kill switches.” Nonetheless, venture capital is flowing into firms pursuing AAV‑based HIV cures, signaling a shift toward gene‑editing solutions as a cornerstone of next‑generation infectious‑disease therapeutics.